Session 2: Therapeutic Degraders as New Class of Prostate Cancer Treatments
Thursday, October 28, 2021 | 8:45 AM – 9:25 AM PST
Moderator: Howard Soule, PhD, Prostate Cancer Foundation
Targeting Enhancer Addiction in Prostate Cancer by Impeding Chromatin Accessibility
Arul M. Chinnaiyan, MD, PhD, University of Michigan, Michigan Center for Translational Pathology
Clinical Development of ARV-110, a Novel AR Degrader, in Prostate Cancer
Debbie Chirnomas, MD, MPH, Arvinas, Inc.